Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases.
| Autor: | Maqbool S; Department of Medicine, Holy Family Hospital, Rawalpindi 46000, Pakistan. hasanshahzaib299@gmail.com., Baloch MF; Department of Community Medicine, Allama Iqbal Medical College, Lahore 45000, Pakistan., Khan MAK; Department of Community Dentistry, Baqai Medical University, Karachi 43000, Pakistan., Khalid A; Department of Medicine, Allama lqbal Medical College, Lahore 45000, Pakistan., Naimat K; Department of MedicineLiaquat University of Medical and Health Sciences, Karachi 43000, Pakistan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of transplantation [World J Transplant] 2024 Mar 18; Vol. 14 (1), pp. 87532. |
| DOI: | 10.5500/wjt.v14.i1.87532 |
| Abstrakt: | Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malig nancies; however, despite being efficacious in various instances, negative consequences have also been recorded. Multiple conditioning regimens were extracted from various literature searches from databases like PubMed, Google scholar, EMBASE, and Cochrane. Conditioning regimens for each disease were compared by using various end points such as overall survival (OS), progression free survival (PFS), and leukemia free survival (LFS). Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen. In multiple myeloma, the most effective regimen was high dose melphalan (MEL) given at a dose of 200/mg/m 2 . The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan (BU) + MEL regarding OS and BU + VP16 regarding LFS. In case of acute lymphoblastic leukemia (ALL), BU, fludarabine, and etoposide (BuFluVP) conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence. However, for ALL, chimeric antigen receptor (CAR) T cell therapy was preferred in the context of better OS and LFS. With respect to Hodgkin's lymphoma, mitoxantrone (MITO)/MEL overtook carmustine, VP16, cytarabine, and MEL in view of PFS and vice versa regarding OS. Non-Hodgkin's lymphoma patients were administered MITO (60 mg/m 2 ) and MEL (180 mg/m 2 ) which showed promising results. Lastly, amyloidosis was considered, and the regimen that proved to be competent was MEL 200 (200 mg/m 2 ). This review article demonstrates a comparison between various conditioning regimens employed in different diseases. Competing Interests: Conflict-of-interest statement: The authors declare that they have no competing interests to disclose. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|